AVIRAtea Pharmaceuticals, Inc.
Earnings
When Atea Pharmaceuticals, Inc. reports, what it reported each quarter, and how the stock took the results.
31 quarters. Mar 31, 2019 to Sep 30, 2026. USD.
Next results · Q4 2026Projected
Mar 4, after the close
Thu, Mar 4, 2027in 108 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Feb 25 – Mar 9
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- —
- Revenue, change from a year earlier: Q4 2021 n/m, Q3 2021 n/m, Q2 2021 n/m, Q1 2021 n/m
- Net income
- -$44.87M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Latest results
- Revenue
- —
- —
- Net income
- -$32.16M
- N/M
- EPS
- -$0.40
- N/M
- Revenue
- —
- —
- Net income
- -$32.93M
- N/M
- EPS
- -$0.41
- N/M
- Revenue
- —
- —
- Net income
- -$45.44M
- N/M
- EPS
- -$0.57
- N/M
- Revenue
- —
- —
- Net income
- -$44.87M
- N/M
- EPS
- —
- —
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | Sep 30, 2026 | Nov 9, 2026 · after-hours | Nov 9, 2026 | 40 d | 10-Q | — | — | -$0.40 | — | |
| Q2 2026 | Jun 30, 2026 | Aug 12, 2026 · after-hours | Aug 12, 2026 | 43 d | 10-Q | — | — | -$0.41 | 0.2% | |
| Q1 2026 | Mar 31, 2026 | May 12, 2026 · after-hours | May 12, 2026 | 42 d | 10-Q | — | — | -$0.57 | 16.9% | |
| FY 2025 | ||||||||||
| Q4 2025derived | Dec 31, 2025 | Mar 5, 2026 · after-hours | Mar 5, 2026 | 64 d | 10-K | — | — | — | +11.1% | |
| Q3 2025 | Sep 30, 2025 | Nov 12, 2025 · after-hours | Nov 12, 2025 | 43 d | 10-Q | — | — | -$0.53 | 12.0% | |
| Q2 2025 | Jun 30, 2025 | Aug 7, 2025 · after-hours | Aug 7, 2025 | 38 d | 10-Q | — | — | -$0.44 | 2.6% | |
| Q1 2025 | Mar 31, 2025 | May 12, 2025 · after-hours | May 12, 2025 | 42 d | 10-Q | — | — | -$0.40 | 11.6% | |
| FY 2024 | ||||||||||
| Q4 2024derived | Dec 31, 2024 | Mar 6, 2025 · after-hours | Mar 6, 2025 | 65 d | 10-K | — | — | — | 0.8% | |
| Q3 2024 | Sep 30, 2024 | Nov 7, 2024 · after-hours | Nov 7, 2024 | 38 d | 10-Q | — | — | -$0.37 | +1.6% | |
| Q2 2024 | Jun 30, 2024 | Aug 7, 2024 · after-hours | Aug 7, 2024 | 38 d | 10-Q | — | — | -$0.48 | — | |
| Q1 2024 | Mar 31, 2024 | May 14, 2024 · after-hours | May 14, 2024 | 44 d | 10-Q | — | — | -$0.75 | — | |
| FY 2023 | ||||||||||
| Q4 2023derived | Dec 31, 2023 | Feb 28, 2024 · after-hours | Feb 28, 2024 | 59 d | 10-K | — | — | — | — | |
| Q3 2023 | Sep 30, 2023 | Nov 8, 2023 · after-hours | Nov 8, 2023 | 39 d | 10-Q | — | — | -$0.40 | — | |
| Q2 2023 | Jun 30, 2023 | Aug 8, 2023 · after-hours | Aug 8, 2023 | 39 d | 10-Q | — | — | -$0.34 | — | |
| Q1 2023 | Mar 31, 2023 | May 8, 2023 · after-hours | May 8, 2023 | 38 d | 10-Q | — | — | -$0.43 | — | |
| FY 2022 | ||||||||||
| Q4 2022derived | Dec 31, 2022 | Feb 28, 2023 · after-hours | Feb 28, 2023 | 59 d | 10-K | — | — | — | 8.2% | |
| Q3 2022 | Sep 30, 2022 | Nov 7, 2022 · after-hours | Nov 7, 2022 | 38 d | 10-Q | — | — | -$0.10 | — | |
| Q2 2022 | Jun 30, 2022 | Aug 8, 2022 · after-hours | Aug 8, 2022 | 39 d | 10-Q | — | — | -$0.38 | — | |
| Q1 2022 | Mar 31, 2022 | May 9, 2022 · after-hours | May 10, 2022 | 40 d | 10-Q | — | — | -$0.51 | +32.1% | |
| FY 2021 | ||||||||||
| Q4 2021derived | Dec 31, 2021 | Feb 28, 2022 · after-hours | Feb 28, 2022 | 59 d | 10-K | $192.18M | — | — | +4.1% | |
| Q3 2021 | Sep 30, 2021 | Nov 11, 2021 · after-hours | Nov 12, 2021 | 43 d | 10-Q | $32.81M | — | -$0.34 | — | |
| Q2 2021 | Jun 30, 2021 | Aug 12, 2021 · after-hours | Aug 12, 2021 | 43 d | 10-Q | $60.39M | — | $0.02 | 11.1% | |
| Q1 2021 | Mar 31, 2021 | May 13, 2021 · after-hours | May 13, 2021 | 43 d | 10-Q | $65.99M | — | $0.34 | +16.1% | |
| FY 2020 | ||||||||||
| Q4 2020derived | Dec 31, 2020 | — | Mar 30, 2021 | 89 d | 10-K | — | — | — | +9.8% | |
| Q3 2020 | Sep 30, 2020 | — | Dec 10, 2020 | 71 d | 10-Q | — | — | -$1.74 | +7.2% | |
| Q2 2020 | Jun 30, 2020 | — | — | — | — | — | — | -$0.99 | — | |
| Q1 2020 | Mar 31, 2020 | — | — | — | — | — | — | -$0.40 | — | |
| FY 2019 | ||||||||||
| Q4 2019derived | Dec 31, 2019 | — | — | — | — | — | — | — | — | |
| Q3 2019 | Sep 30, 2019 | — | — | — | — | — | — | -$0.36 | — | |
| Q2 2019 | Jun 30, 2019 | — | — | — | — | — | — | — | — | |
| Q1 2019 | Mar 31, 2019 | — | — | — | — | — | — | — | — | |
Earlier years, FY 2019 to FY 2023The latest three years
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Source filings
Provenance
ProvenanceData status and checks
Atea Pharmaceuticals, Inc. · CIK 1593899 · Engraved from SEC EDGAR